Novavax has released data from its phase III COVID-19 vaccine candidate study that demonstrates it as effective against the Kent variant of the virus. Conducted during the period when the Kent COVID-19 variant was first observed, the phase III trial has shown the vaccine to be 89.3% effective in preventing coronavirus in participants, as well [ ]
The post Novavax COVID-19 vaccine shows efficacy against Kent variant appeared first on Health Europa.
Saturday 6 March 2021
Latest News
